Skip to content Skip to footer
Subscribe Now

EXCLUSIVE

Exclusive_Dr. Ikshit Sharma_2025
Exclusive Coverage: Dr. Ikshit Sharma from AIMIL Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots
Shots: Integrating innovation with the scientific principles of Ayurveda, AIMIL Pharmaceuticals caters to the growing needs of healthcare professionals, patients, and the animal healthcare sector PharmaShots welcomes Dr. Ikshit Sharma, Director at AIMIL Pharmaceuticals, in a riveting conversation. Ikshit stresses the significance of making investments in research and development for creating novel therapies and addressing…
January 20, 2025
Exclusive_Chris Heery_2024
Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots
Shots:  Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM)  Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma  In late 2022,…
September 30, 2024
Exclusive_Moitreyee Chatterjee-Kishore_2024
Decoding Approval: Moitreyee Chatterjee-Kishore from Astellas in an Exclusive Conversation with PharmaShots
Shots:  Recently EC granted Marketing Authorization to Astellas’ VYLOY (zolbetuximab) in combination with chemotherapy for the treatment of patients with advanced gastric and GEJ cancers  Zolbetuximab, a monoclonal antibody designed to target gastric tumor cells that express CLDN18.2 biomarker  Today, at PharmaShots we have Dr. Moitreyee Chatterjee-Kishore the Head of Development, Immuno-Oncology and Cancer Cell…
September 26, 2024
Exclusive_Ahsan Arozullah_2024
Advancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots
Shots:  Recently, the CHMP of the EMA adopted a positive opinion for Astellas’ Padcev + Keytruda combination therapy as the first-line treatment of patients with unresectable or metastatic urothelial cancer  Today, in an exclusive coverage, we bring an enlightening conversation with Ahsan Arozullah from Astellas Pharma, sharing insights from the P-III EV-302 study  Astellas looks…
September 4, 2024
Exclusive Interview_David Esposito
Exclusive: David Esposito in an Illuminating Discussion with PharmaShots
Shots:  Our recent Spotlight interview with David Esposito, CEO at ONL therapeutics became a major hit on the internet. We were moved by the overwhelming response from the netizens  Here we have again, David Esposito in an engaging conversation with PharmaShots. David discusses in great length about the company’s lead candidate ONL1204, currently being evaluated…
March 12, 2024
Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]